☆ 4.6 Article

Long-term outcomes among adults with Langerhans cell histiocytosis

BLOOD ADVANCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis

Gaurav Goyal et al.

Summary: With the use of the SEER database, this study explored the patterns of second primary malignancies (SPMs) and cause-specific mortality among individuals with Langerhans cell histiocytosis (LCH) from 2000 to 2016. The study found an increased risk of SPMs in the LCH cohort, with the pediatric group having a high risk of Hodgkin lymphoma and non-Hodgkin lymphoma, and adults having a high risk of miscellaneous malignant cancers. The study emphasizes that despite advances in treatments, people with LCH have an increased risk of mortality from non-LCH causes, including a high risk of SPMs.

LEUKEMIA RESEARCH (2023)

添加到收藏夹

Letter Hematology

BARFV600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Aldo A. Acosta-Medina et al.

BLOOD (2023)

添加到收藏夹

Article Hematology

Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis

Xin-xin Cao et al.

Summary: BRAF deletion is associated with multi-system LCH, while liver or spleen involvement at baseline indicates a poor prognosis. Cytarabine-based therapy may be beneficial as a first-line treatment for adult LCH patients.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Respiratory System

Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort

Amira Benattia et al.

Summary: This study aims to investigate the long-term outcomes of adult PLCH. The findings suggest that the prognosis of PLCH is more favorable than previously reported. Therefore, close monitoring after diagnosis is crucial for early detection of severe complications.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Hematology

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

Gaurav Goyal et al.

Summary: Langerhans cell histiocytosis (LCH) is a disease that can affect children and adults, with various clinical manifestations. Recent research suggests that LCH can be considered as a hematopoietic neoplasm and can be treated with targeted therapies. Therefore, an update of the existing recommendations for the diagnosis and treatment of LCH in adults is necessary. The use of F-18-Fluorodeoxyglucose positron emission tomography-based imaging is recommended for staging and response assessment in most cases. Local therapies may cure unifocal disease, while systemic treatments are recommended for patients with multifocal and multisystem disease. Appropriate management of symptoms such as pain, fatigue, and mood disorders is important.

BLOOD (2022)

添加到收藏夹

Letter Oncology

Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis

Marie Hu et al.

BLOOD CANCER JOURNAL (2022)

添加到收藏夹

Article Hematology

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013-2019

Hanhua Liu et al.

Summary: This study provides the largest population-based epidemiological estimates of Langerhans cell histiocytosis (LCH) in England. The analysis reveals higher incidence and prevalence rates of LCH in children, as well as lower overall survival rates in patients aged 60 and above. Additionally, individuals in deprived areas have lower survival rates.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Oncology

Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients

Francesca Bagnasco et al.

Summary: This study analyzed the co-occurrence of Langerhans cell histiocytosis (LCH) and associated malignancies (AM) in children and adults. The results showed inherent relationships between specific types of AM and LCH, possibly due to therapy effects, clonal evolution, and germ-line predisposition. Further prospective genetic analysis is needed to shed light on the association between LCH and second neoplasms.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Hematology

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart et al.

Summary: Erdheim-Chester disease (ECD) patients have a high frequency of clonal hematopoiesis, which may lead to the development of myeloid neoplasms. Patients with clonal hematopoiesis are typically older, have retroperitoneal involvement, and harbor a BRAF(V600E) mutation.

BLOOD (2021)

添加到收藏夹

Editorial Material Hematology

CHIPping away at Erdheim-Chester disease

Gaurav Goyal

Summary: The study found a high prevalence of mutations associated with clonal hematopoiesis in patients with Erdheim-Chester disease, shedding light on the molecular mechanisms of ECD and its known association with other myeloid neoplasms.

BLOOD (2021)

添加到收藏夹

Article Hematology

Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival

Antonious Z. Hazim et al.

Summary: Langerhans cell histiocytosis (LCH) can involve the lungs as single system (LCH-SSL) or multisystem disease (LCH-MSL). The utility of full-body radiographic staging in LCH patients at presentation is unclear. Patients with isolated pulmonary signs or symptoms rarely develop extra-pulmonary disease, with LCH-SSL showing the best overall survival compared to LCH-MSL and LCH-MSNL.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms

Gaurav Goyal et al.

HAEMATOLOGICA (2020)

添加到收藏夹

Letter Hematology

Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study

Xin-Xin Cao et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

添加到收藏夹

Editorial Material Oncology

Efficacy ofBRAF-InhibitorTherapy in BRAFV600E-MutatedAdult Langerhans Cell Histiocytosis

Antonious Z. Hazim et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Efficacy of MEK inhibition in patients with histiocytic neoplasms

Eli L. Diamond et al.

NATURE (2019)

添加到收藏夹

Letter Hematology

Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin

Gaurav Goyal et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

Benjamin H. Durham et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Oncology

Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies

Jennifer Ma et al.

CANCER MEDICINE (2019)

添加到收藏夹

Review Oncology

Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas

E. Ann Yeh et al.

PEDIATRIC BLOOD & CANCER (2018)

添加到收藏夹

Article Oncology

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

Eli L. Diamond et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Letter Hematology

Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes

Gaurav Goyal et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

添加到收藏夹

Article Hematology

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis

Matthias Papo et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

J.-F. Emile et al.

BLOOD (2016)

添加到收藏夹

Article Oncology

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

Sebastien Heritier et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Hematology

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Rikhia Chakraborty et al.

BLOOD (2014)

添加到收藏夹

Article Hematology

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

Helmut Gadner et al.

BLOOD (2013)

添加到收藏夹

Review Genetics & Heredity

Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

Michael Girschikofsky et al.

ORPHANET JOURNAL OF RARE DISEASES (2013)

添加到收藏夹

Article Hematology

Recurrent BRAF mutations in Langerhans cell histiocytosis

Gayane Badalian-Very et al.

BLOOD (2010)

添加到收藏夹

Article Oncology

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

GR Goodman et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.